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OBJECTIVES We sought to determine whether the clinical effects of early angiotensin-converting enzyme
(ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the
concomitant use of aspirin (ASA).
BACKGROUND Aspirin and ACEi both reduce mortality when given early after MI. Aspirin inhibits the
synthesis of vasodilating prostaglandins, and, in principle, this inhibition might antagonize
some of the effects of ACEi. But it is uncertain whether, in practice, this influences the effects
of ACEi on mortality and major morbidity after MI.
METHODS This overview sought individual patient data from all trials involving more than 1,000 patients
randomly allocated to receive ACEi or control starting in the acute phase of MI (0–36 h from
onset) and continuing for four to six weeks. Data on concomitant ASA use were available for
96,712 of 98,496 patients in four eligible trials (and for none of 1,556 patients in the one
other eligible trial).
RESULTS Overall 30-day mortality was 7.1% among patients allocated to ACEi and 7.6% among those
allocated to control, corresponding to a 7% (standard deviation [SD], 2%) proportional
reduction (95% confidence interval 2% to 11%, p 5 0.004). Angiotensin-converting enzyme
inhibitor was associated with similar proportional reductions in 30-day mortality among the
86,484 patients who were taking ASA (6% [SD, 3%] reduction) and among the 10,228
patients who were not (10% [SD, 5%] reduction: chi-squared test of heterogeneity between
these reductions 5 0.4; p 5 0.5). Angiotensin-converting enzyme inhibitor produced definite
increases in the incidence of persistent hypotension (17.9% ACEi vs. 9.4% control) and of
renal dysfunction (1.3% ACEi vs. 0.6% control), but there was no good evidence that these
effects were different in the presence or absence of ASA (chi-squared for heterogeneity 5 0.4
and 0.0, respectively; both not significant). Nor was there good evidence that the effects of
ACEi on other clinical outcomes were changed by concomitant ASA use.
CONCLUSIONS Both ASA and ACEi are beneficial in acute MI. The present results support the early use of
ACEi in acute MI, irrespective of whether or not ASA is being given. (J Am Coll Cardiol
2000;35:1801–7) © 2000 by the American College of Cardiology
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Angiotensin-converting enzyme (ACE) inhibitors (ACEi)
have been shown to improve prognosis not only when started
some time after myocardial infarction (MI) in patients with
evidence of left ventricular dysfunction (1–3) but also when
given during the acute phase of MI in relatively unselected
patients (4–8). Overall, in a recently published overview of the
large-scale randomized trials, early ACEi treatment of acute
MI produced a small but highly significant 7% (standard
deviation [SD], 2%) proportional reduction (2 p , 0.004) in
30-day mortality, which corresponded to avoidance of an
average of five deaths per 1,000 patients treated for one month
(9). Aspirin (ASA), which is an inhibitor of platelet cyclo-
oxygenase and prostaglandin synthesis, produces a much larger
(27% [SD, 3%]) proportional decrease in mortality or major
morbidity in this setting (10,11) and has, for some years, been
used widely.
See page 1808
One of the most prominent pharmacologic actions of
ACEi is to decrease arterial pressure, and this seems to be
mediated not only by a reduction in angiotensin II produc-
tion but also by an increase in bradykinin (12) and in the
vasodilating prostaglandins I2 and E2 (13,14). The absence
of a reflex increase in heart rate when blood pressure is
lowered with ACEi may be partly attributable to the
increased production of prostaglandins (15) and the increase
in baroreflex gain resulting from lowered levels of angioten-
sin II in the central nervous system (16), and at least the first
of these two effects might be inhibited by ASA. Moreover,
ACEi treatment has been associated with depression of
renal function, and it has been suggested that ASA might
potentiate this unwanted action of ACEi by decreasing
renal vasodilatory prostaglandin synthesis and increasing
sodium and water retention (17).
It has been claimed that ASA reduces the blood pressure
lowering effect of ACEi (18) and the short-term beneficial
hemodynamic effects of ACEi in heart failure patients
(19–21), although the latter findings were not confirmed by
another study (17). A retrospective subanalysis of about
7,000 patients with left ventricular dysfunction in the
Studies of Left Ventricular Dysfunction (SOLVD) trials
showed a trend toward less benefit with ACEi in patients
using antiplatelet agents at baseline (published only as an
abstract [22]), but, again, these findings have not been
confirmed by other long-term trials of ACEi.
In the context of acute MI, a preliminary analysis of 19,000
patients in the Gruppo Italiano per lo Studio della Sopravvi-
enza nell’Infarto Miocardico (GISSI)-3 trial did not indicate
any impact of ASA on the clinical effects of ACEi, whereas
analyses of 6,000 in the Cooperative New Scandinavian Ena-
lapril Survival Study (CONSENSUS) II trial did indicate a
nonsignificant interaction (23). More recently, a post-hoc
analysis of the few (298) acute MI patients enrolled in the
Captopril And Thrombolysis Study trial did not suggest that
ASA attenuated the acute and long-term beneficial effects of
ACEi on left ventricular function (24).
To help determine more reliably whether the effects of
ACEi on mortality, or on other clinical outcomes, are
materially altered by the use of concomitant ASA, we have
analyzed the data on nearly 97,000 patients in the overview
of the large trials of early ACEi treatment in acute MI.
METHODS
The overview was to include individual patient data from all
randomized trials involving more than 1,000 patients in which
ACEi treatment was started in the acute phase of MI (0 to
36 h from symptom onset) and continued for a short period of
time (generally four to six weeks). Individual data were avail-
able for 98,496 patients from four such trials (Chinese Cardiac
Study [CCS]-1 [4], CONSENSUS II [5], GISSI-3 [6] and
International Study of Infarct Survival [ISIS]-4 [7]) but not for
1,556 patients in the one other eligible trial Survival of
Myocardial Infarction Long-term Evaluation (3). The meth-
ods and main results of this overview have been presented in
detail elsewhere (9). Information on ASA or other antiplatelet
use (yes/no) at randomization was available for 96,712 of these
patients, on which the present analyses are based: 86,484 were
receiving antiplatelet therapy and 10,228 were not. The Chi-
nese Cardiac Study-1 recorded the use of ASA alone, whereas
the other three trials recorded ASA plus other antiplatelet
agents, but it is reasonable to assume that the use of antiplate-
lets other than ASA early after MI was very low. Hence, for
the purposes of these analyses, antiplatelet use is considered to
be synonymous with ASA use. Information on ASA dose
received by each patient was not available, although the
protocol for CCS-1 recommended 160 mg daily.
Statistical methods. The primary analyses were of the
effects of ACEi on total mortality and were recorded up to
day 30. Secondary analyses were of mortality from day 0 to
day 7 and of other clinical events (persistent hypotension,
renal dysfunction, stroke, reinfarction and nonfatal heart
failure) up to day 30. Only the first occurrence of each
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ACEi 5 angiotensin-converting enzyme
inhibitor
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adverse event was recorded, so the analyses are of the
number of patients with at least one such event. The
analyses were conducted with SAS software. Chi-squared
tests were used to compare patients’ baseline characteristics.
For the survival analyses, the Kaplan-Meier method was
used and the p value was calculated by the log-rank test. All
such p values are two sided. The Mantel-Haenszel method
was used to calculate stratified estimates of the proportional
effects (odds ratios and percent reductions in odds) of
ACEi, and comparisons of these effects in the presence and
absence of ASA involved chi-squared tests for heterogene-
ity.
RESULTS
The prevalence of ASA use at entry was very different in the
four studies (Table 1), ranging from 75% in CCS-1 to 94%
in ISIS-4. Patients not receiving ASA at entry were older
than those who were receiving ASA (Table 2) and also
differed in terms of gender, previous history of MI, severity
of MI, use of thrombolytics and use of beta-adrenergic
blocking agents (Table 2).
Effects of ACEi on mortality. Overall, 30-day mortality
was 7.1% among patients allocated to ACEi and 7.6%
among those allocated to control, corresponding to a 7%
(SD, 2%) proportional reduction (95% confidence interval
2% to 11%; 2 p , 0.004: Fig. 1). No significant difference
was observed between the proportional effects of ACEi on
mortality in the four studies. Angiotensin-converting en-
zyme inhibitor was associated with similar proportional
reductions in 30-day mortality among the 86,484 patients
who were taking ASA (6% [SD, 3%] reduction) and among
the 10,228 who were not (10% [SD, 5%] reduction: chi-
squared for heterogeneity on one degree of freedom 5 0.4;
p 5 0.5: Fig. 1 and 2).
Likewise, the overall proportional reduction in seven-day
mortality with ACEi of 9% (SD, 3%) (p 5 0.002), the so
called “early benefit” (9), was not significantly different in
the presence of ASA (7% [SD, 3%] reduction) or in its
absence (15% [SD, 6%] reduction: chi-squared for hetero-
geneity 5 1.3; p 5 0.3).
Effects of ACEi on other clinical events. Overall, ACEi
doubled the incidence of persistent hypotension and renal
dysfunction (Fig. 3A), but there was no suggestion that the
effects of ACEi on these outcomes were different in the
presence and absence of ASA: chi-squared for heterogene-
ity 5 0.4 for persistent hypotension (p 5 0.5) and 0.0 for
renal dysfunction (p 5 0.9).
Angiotensin-converting enzyme inhibitor reduced the
incidence of nonfatal heart failure, but, again, the propor-
tional effect among patients receiving ASA was not signif-
icantly different from that among those who were not
receiving ASA (chi-squared for heterogeneity on 1 df 5 1.3:
p 5 0.3). The 30-day reinfarction rate was not affected by
ACEi among those receiving ASA and among those who
were not. Nor was the overall 30-day stroke rate signifi-
cantly affected by ACEi (1.02% ACEi vs. 0.95% control),
and, although there appeared to be a trend towards slightly
more strokes with ACEi in the presence of ASA (1.0%
ACEi vs. 0.8% control) and slightly fewer in the absence of
ASA (1.5% ACEi vs. 2.0% control), there was no good
evidence of an effect of ACEi on stroke in either circum-
stance. In general, the effects of ACEi on all of the clinical
events examined were not shown to be influenced by ASA
(global chi-squared for heterogeneity between all subgroups
in Fig. 1 and 3 5 8.2: p 5 0.2 with 6 df).
DISCUSSION
Mortality. This study indicates that, in terms of the pro-
portional reduction in 30-day mortality after hospital ad-








CCS-1 captopril 11,134/14,884 75
CONSENSUS II enalapril 4,787/6,090 79
GISSI-3 lisinopril 16,717/18,711 89
ISIS-4 captopril 53,846/57,027 94
Total various 86,484/96,712 89
**Percentages are of patients with information available on antiplatelet use at study entry (see Methods section).
For acronyms see Abbreviation box.






Age $ 65 yr 45% 51%
Women 25% 29%
SBP # 120 mm Hg 40% 42%
HR $ 80 beats/min 45% 48%
Previous MI 16% 18%
Heart failure (Killip 2–3) 17% 26%
Anterior MI 37% 40%
Thrombolytic used 66% 40%
I.V. beta-blocker used 13% 7%
All 9 Comparisons ASA vs. no-ASA (chi-squared) p , 0.0001.
ASA 5 aspirin; HR 5 heart rate; I.V. 5 intravenous; MI 5 myocardial infarction;
SBP 5 systolic blood pressure.
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mission for acute MI, the benefits of ASA and the benefits
of ACEi are approximately independent of each other, in
which case the greater benefit will be obtained by using both
treatments. In particular, Figure 1 shows that the hypoth-
esis, generated by subgroup analyses of one particular study
(23) that ACEi would be ineffective in ASA-treated pa-
tients, is refuted by the other studies in this meta-analysis,
which collectively include much larger numbers of patients.
Other clinical events. Moreover, ASA does not signifi-
cantly modify the safety profile of early ACEi. In particular,
the results obtained on renal dysfunction, which is a serious,
although infrequent, complication of ACEi treatment,
show that even in that target organ no clinically relevant
interaction between ACEi and ASA occurs. The large
number of patients, hospitals and countries involved in these
trials strongly suggests that there are no clinically important
interactions between ACEi and ASA in a range of settings
during the first month after acute MI. The apparently
contrasting effects of ACEi on stroke in the presence and
absence of ASA should not be overemphasized, and, con-
sidering the large number of comparisons done, might well
be due merely to the play of chance, especially since there
appears to be no clear rationale for such an interaction.
If we apply power calculations to the clinical event with
the lowest incidence, renal dysfunction, an increase in odds
ratio for renal dysfunction in ASA group from 1.93 (ACEi
vs. control) to 3, could be arbitrarily chosen as clinically
relevant. This means an increase from 1.3% (Fig. 3A) to
1.8% in the incidence of renal dysfunction in patients taking
both ACEi and ASA (n 5 43,174) or an absolute increase
of 0.5%, corresponding to a 35% relative increase. Applica-
tion of power calculations yields a value of 1-beta 5 0.99
with an alpha 5 0.01 (a subgroup analysis being performed).
The power for other events with higher incidence will
necessarily be .0.99. These considerations on statistical
power should help in critically interpreting previous claims
on the existence or nonexistence of an interaction between
ASA and ACEi, based on analyses of smaller populations of
patients (19–21,23–25).
ASA schedules. Although the available data did not allow us
to determine directly various aspects of the ASA treatment
(such as dose, time of initiation, duration), we can reasonably
assume, based on recommendations in the protocols of at least
two of the largest studies (6,7) that ASA began as soon as
possible after the onset of symptoms, and its use was recorded
within 36 h of onset before randomization of ACEi. More-
Figure 1. Proportional effect of ACEi therapy on 30-day mortality in the presence and absence of concomitant ASA. The odds ratio for
each trial is represented by a square (area proportional to number of patients with an event), with 99% CI (horizontal line). The overall
results for the trials and their 95% CI are represented by diamonds. ACEi 5 angiotensin-converting enzyme inhibitor; ASA 5 aspirin;
CI 5 confidence intervals.
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over, although only CCS-1 specified the ASA dose (160 mg
daily), it is likely that the doses of ASA used in other studies
were also generally in the range of 160 to 325 mg daily (10,11).
Antiplatelet agents other than ASA were likely to have been
used relatively infrequently; indeed, in GISSI-3 they were used
in only 4% of patients during hospitalization, whereas 89%
used ASA. Therefore, it can reasonably be assumed that the
use of non-ASA antiplatelet agents is unlikely to have distorted
the present analyses to any material extent. It can also be
assumed that ASA was continued upon discharge in most
patients; for example, in GISSI-3 78% of those on ASA at
entry were still on ASA when discharged alive from the
hospital.
ASA use in good and in poor prognosis patients. The
lower mortality and lower rate of some other adverse events
in patients receiving ASA must, to some extent, reflect the
benefits of ASA (10). But it also reflects the fact that, on
average, the patients not receiving ASA were older and
more severely ill, and, therefore, had a worse prognosis than
those who were receiving ASA (26). It is unclear why a drug
like ASA, which is easy to administer, safe and of proven
benefit during and after MI (10,11) should not be offered to
almost all patients, especially those presenting with a poor
prognosis. Perhaps this reflected previous attitudes to ASA
use in older individuals (with undue concerns about adverse
effects), since even at discharge ASA use appeared to be
Figure 2. Randomized comparison of ACEi versus no-ACEi on 30-day mortality in (poor-average prognosis) patients who were not given
ASA and in (good-average prognosis) patients who were given ASA. Note that although ASA must have been responsible for some
benefit, differences in prognosis between patients may well be responsible for more than half of the difference in outcome between ASA
and no-ASA in this Figure.
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slightly less in older patients (for example, in GISSI-3 it was
given to 88% of those aged $65 years compared with 91%
of those aged ,65 years).
Conclusions. The present analyses of clinical outcomes
among nearly 97,000 MI patients show that ACEi are safe
and moderately effective when given early after MI, irre-
spective of whether (as will normally be the case nowadays)
ASA is also being given. Likewise, despite the suggestion of
an interaction with ASA in SOLVD (22), consideration
together of all large trials of long-term ACEi in MI patients
with signs or symptoms of left ventricular dysfunction (1–3)
Figure 3. (A) Effects of ACEi therapy on 30-day incidence of persistent hypotension and renal dysfunction in the presence and absence
of concomitant ASA. (B) Effects of ACEi therapy on 30-day incidence of heart failure, reinfarction and stroke in the presence and absence
of concomitant ASA. *Percentages for heart failure are of patients surviving at day 30; **CONSENSUS-II patients are excluded from this
analysis because data on stroke were not available.
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shows that ACEi is of additional value even in patients who
are being given ASA.
Guidelines suggesting a possible negative interaction
between ASA and ACEi in the setting of MI now need to
be reconsidered.
APPENDIX
THE ACE INHIBITOR MYOCARDIAL INFARCTION
COLLABORATIVE GROUP:
Steering Committee (early and late trials): GISSI-3: L.
Tavazzi, G. Tognoni. ISIS-4: R. Collins, C. Baigent, M.
Flather, R. Peto, P. Sleight. CCS-1: Z-M. Chen, L-S. Liu,
W. Wang. CONSENSUS II: J. Kjekshus, K. Swedberg.
AIRE: S. Ball. TRACE: L. Køber, C. Torp-Pedersen.
SAVE: E. Braunwald, L. Moye´, M. Pfeffer. SOLVD: S.
Yusuf.
Coordinating Centers: Early trials: Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto Miocardico
(GISSI): M.G. Franzosi, R. Latini, A.P. Maggioni, E.
Santoro, L. Santoro, G. Zuanetti. Late trials: Canadian
Cardiovascular Collaboration (CCC), McMaster Clinic: M.
Flather, J. Pogue, Y. Wang, S. Yusuf.
Acknowledgments
We thank Luisa Galbiati for the invaluable secretarial
support in communications within the Collaborative Group
and in manuscript preparation.
Reprint requests and correspondence: Dr. Roberto Latini, De-
partment of Cardiovascular Research, Istituto Mario Negri, Via
Eritrea, 62, 20157 Milano, Italy. E-mail: latini@irfmn.mnegri.it.
REFERENCES
1. Pfeffer MA, Braunwald E, Moye´ LA, et al., for the SAVE Investiga-
tors.. Effect of captopril on mortality and morbidity in patients with
left ventricular dysfunction after myocardial infarction: results of the
Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med
1992;327:669–77.
2. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
Effect of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure. Lancet
1993;342:821–8.
3. Kober L, Torp-Pedersen C, Carlsen JE, et al., for the TRAndolapril
Cardiac Evaluation (TRACE) Study Group. A clinical trial of the
angiotensin-converting enzyme inhibitor trandolapril in patients with
left ventricular dysfunction after myocardial infarction. N Engl J Med
1995;333:1670–6.
4. Chinese Cardiac Study Collaborative Group. Oral captopril versus
placebo among 13,634 patients with suspected acute myocardial
infarction: interim report from the Chinese Cardiac Study (CCS-1).
Lancet 1995;345:686–7.
5. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryde´n L, Wedel H,
for the CONSENSUS II Study Group. Effects of the early adminis-
tration of enalapril on mortality in patients with acute myocardial
infarction. N Engl J Med 1992;327:678–84.
6. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Mio-
cardico. GISSI-3: effects of lisinopril and transdermal glyceryl trini-
trate singly and together on six-week mortality and ventricular func-
tion after acute myocardial infarction. Lancet 1994;343:1115–22.
7. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial
assessing early oral captopril, oral mononitrate and intravenous mag-
nesium sulphate in 58,050 patients with suspected acute myocardial
infarction. Lancet 1995;345:669–85.
8. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial
Infarction Long-term Evaluation (SMILE) Study Investigators. The
effect of the angiotensin-converting-enzyme inhibitor zofenopril on
mortality and morbidity after anterior myocardial infarction. N Engl
J Med 1995;332:80–5.
9. ACE Inhibitor Myocardial Infarction Collaborative Group. Indica-
tions for ACE inhibitors in early treatment of acute myocardial
infarction. Systematic overview of individual data from 100,000
patients in randomized trials. Circulation 1998;97:2202–12.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomized trial of intravenous streptokinase, oral aspirin,
both or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. Lancet 1988;ii:349–60.
11. Antiplatelet Trialists’ Collaboration. Collaborative overview of ran-
domized trials of antiplatelet therapy. I: Prevention of death, myocar-
dial infarction and stroke by prolonged antiplatelet therapy in various
categories of patients. Br Med J 1994;308:81–106.
12. Blais C, Drapeau G, Raymond P, et al. Contribution of angiotensin-
converting enzyme to the cardiac metabolism of bradykinin: an
interspecies study. Am J Physiol 1997;273:H2263–71.
13. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG,
Moore TJ. Captopril-induced changes in prostaglandin production.
Relationship to vascular responses in normal man. J Clin Invest
1980;65:1257–64.
14. Packer M. Interaction of prostaglandins and angiotensin II in the
modulation of renal function in congestive heart failure. Circulation
1988;77 Suppl I:I64–73.
15. Zucker IH, Chen J-S, Wang W. Renal sympathetic nerve and
hemodynamic responses to captopril in conscious dogs: role of pros-
taglandins. Am J Physiol 1991;260:H260–66.
16. Heesch CM, Crandall E, Turbek JA. Converting enzyme inhibitors
cause pressure-independent resetting of baroreflex control of sympa-
thetic outflow. Am J Physiol 1996;270:R728–37.
17. Sturrock NDC, Struthers AD. Nonsteroidal anti-inflammatory drugs
and angiotensin converting enzyme inhibitors: a commonly prescribed
combination with variable effects on renal function. Br J Clin Pharmac
1993;35:343–8.
18. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs—
differences and similarities. N Engl J Med 1991;324:1716–25.
19. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator
effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol
1992;20:1549–55.
20. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemody-
namic interaction of aspirin and ticlopidine with enalapril. Circulation
1998;98:757–65.
21. Baur LHB, Schipperheyn JJ, van der Laarse A, et al. Combining
salicylate and enalapril in patients with coronary artery disease and
heart failure. Br Heart J 1995;73:227–36.
22. Pitt B, Yusuf S, for the SOLVD Investigators. Studies of left
ventricular dysfunction (SOLVD): subgroup results. J Am Coll Car-
diol 1992;19:215A.
23. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and
aspirin on mortality after acute myocardial infarction: subgroup anal-
ysis of the Cooperative New Scandinavian Enalapril Survival Study II
(CONSENSUS II). Am J Cardiol 1997;79:115–9.
24. Oosterga M, Anthonio RL, de Kam P-J, Kingma JH, Crijns HJGM,
van Gilst WH. Effects of aspirin on angiotensin-converting enzyme
inhibition and left ventricular dilation one year after acute myocardial
infarction. Am J Cardiol 1998;81:1178–81.
25. Leor J, Riecher-Reiss H, Goldbrourt U, et al. Aspirin and mortality in
patients treated with angiotensin-converting enzyme inhibitors. A
cohort study of 11,575 patients with coronary artery disease. J Am Coll
Cardiol 1999;33:1920–5.
26. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the
treatment of acute myocardial infarction in elderly Medicare benefi-
ciaries: patterns of use and outcomes. Circulation 1995;92:2841–7.
1807JACC Vol. 35, No. 7, 2000 Latini et al.
June 2000:1801–7 Aspirin/ACE Inhibitor Interaction
